Page last updated: 2024-09-04

moxifloxacin and gemifloxacin

moxifloxacin has been researched along with gemifloxacin in 59 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (gemifloxacin)	Trials (gemifloxacin)	Recent Studies (post-2010) (gemifloxacin)
3,157	552	1,690	320	46	80

Protein Interaction Comparison

Protein	Taxonomy	gemifloxacin (IC50)
DNA gyrase subunit B	Staphylococcus aureus	5.6
DNA gyrase subunit A	Escherichia coli K-12	0.5
DNA gyrase subunit B	Escherichia coli K-12	0.5
DNA topoisomerase 4 subunit A	Staphylococcus aureus	0.3
DNA gyrase subunit A	Staphylococcus aureus	5.6

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (57.63)	29.6817
2010's	23 (38.98)	24.3611
2020's	2 (3.39)	2.80

Authors

Authors	Studies
Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M	1
Bradbury, BJ; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Ou, Y; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA	1
Klugman, KP; Levin, BR; McGee, L; Rozen, DE	1
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA	1
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA	1
Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B	1
Bradbury, BJ; Cheng, J; Deshpande, M; Pucci, MJ; Thanassi, JA; Thoma, CL	1
Morgan-Linnell, SK; Zechiedrich, L	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K	1
Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K	1
Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC	1
Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS	1
Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E	1
Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA	1
Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ	1
Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F	1
Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH	1
Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA	1
Bradbury, BJ; Deshpande, M; Phadke, AS; Pucci, MJ; Thanassi, JA; Wiles, JA	1
Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F	1
Chai, Y; Guo, HY; Li, SJ; Liu, ML; Wang, B; Wang, JX; Zhang, YB	1
Feng, LS; Guo, HQ; Liu, ML; Lv, K; Sun, LY; Sun, YX; Wei, ZQ	1
Cao, J; Feng, L; Guo, H; Li, S; Liu, M; Lv, K; Wang, S; You, X; Zhao, J	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Blaskovich, MAT; Pham, TDM; Ziora, ZM	1
Brady, SF; Koirala, B; Peek, J	1
Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C	1
Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H	1
Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W	1
Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K	1
Rossi, C; Sternon, J	1
Goldstein, EJ	1
Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE	1
Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH	1
Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J	1
Leggett, J; Saravolatz, LD	1
Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA	1
Martinez, FJ	1
Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D	1
Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP	1
Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J	1
Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM	1
Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C	1
Bast, DJ; De Azavedo, JC; Downar, J; Duncan, CL; Kilburn, L; Kong, B; Lad, S; Low, DE	1
Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG	1
Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG	1
Horstkotte, MA; Knobloch, JK; Mack, D; Rohde, H; Von Osten, H	1
Hsueh, PR; Lee, PI; Yang, JC	1
Schafer, KR; Wispelwey, B	1
Lemaire, S; Marquez, B; Mingeot-Leclercq, MP; Ngabirano, E; Tulkens, PM; Vallet, CM; Van Bambeke, F	1
Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ	1
Cass, QB; Denadai, M	1
Bisignano, G; Blanco, AR; Ginestra, G; Marino, A; Nostro, A	1
Ashfaq, M; Faizan Nazar, M; Iqbal, J; Mulla, SI; Mustafa, G; Nawaz Khan, K; Saif Ur Rehman, M; Sun, Q; Yu, CP	1
Attaran, B; Eskini, N; Esmaeili, M; Mohammadi, M; Sadeghi, M; Salehi, N; Sharifirad, A	1
Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J	1

Reviews

4 review(s) available for moxifloxacin and gemifloxacin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Quinolone antibiotics. MedChemComm, 2019, Oct-01, Volume: 10, Issue:10 Topics:	2019
[Third and fourth generation fluoroquinolones]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:5 Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome	2001
Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert review of anti-infective therapy, 2010, Volume: 8, Issue:11 Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae	2010

Other Studies

55 other study(ies) available for moxifloxacin and gemifloxacin

Article	Year
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. Journal of medicinal chemistry, 2003, Mar-13, Volume: 46, Issue:6 Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship	2003
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorganic & medicinal chemistry letters, 2006, Mar-01, Volume: 16, Issue:5 Topics: Anti-Bacterial Agents; Azo Compounds; Cell Line; Escherichia coli; Humans; Hydrocarbons, Aromatic; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Staphylococcus aureus; Sulfhydryl Compounds	2006
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial	2007
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. Journal of medicinal chemistry, 2007, Jan-25, Volume: 50, Issue:2 Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors	2007
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles	2007
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae	2007
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Staphylococcus aureus; Thiazoles; Topoisomerase II Inhibitors	2007
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation	2007
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2007
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae	2008
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6 Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan	2008
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines	2009
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes	2010
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae	2010
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae	2010
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. Bioorganic & medicinal chemistry, 2010, Aug-15, Volume: 18, Issue:16 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors	2010
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin	2010
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA). Journal of medicinal chemistry, 2011, May-12, Volume: 54, Issue:9 Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors	2011
Selenophene-containing inhibitors of type IIA bacterial topoisomerases. Journal of medicinal chemistry, 2011, May-12, Volume: 54, Issue:9 Topics: Anti-Bacterial Agents; Cell Line, Tumor; DNA Topoisomerase IV; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Organoselenium Compounds; Piperidines; Quinolines; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Topoisomerase II Inhibitors	2011
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents. Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors	2011
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Line; Cell Survival; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fluoroquinolones; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcus; Stereoisomerism; Structure-Activity Relationship	2011
Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds. European journal of medicinal chemistry, 2012, Volume: 47, Issue:1 Topics: Animals; Anti-Bacterial Agents; Bacteria; Male; Mice; Naphthyridines; Oximes; Pyrrolidines	2012
Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety. European journal of medicinal chemistry, 2012, Volume: 55 Topics: Anti-Bacterial Agents; Bacteria; Chemistry Techniques, Synthetic; Fluoroquinolones; Gemifloxacin; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Naphthyridines; Oximes	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. Journal of medicinal chemistry, 2013, Mar-14, Volume: 56, Issue:5 Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae	2013
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. Bioorganic & medicinal chemistry letters, 2022, 02-01, Volume: 57 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus	2022
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines	2000
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:8 Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines	2000
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. International journal of antimicrobial agents, 2000, Volume: 16, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections	2000
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy, 2001, Volume: 48, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Serotyping; Streptococcus pneumoniae	2001
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-01, Volume: 35, Issue:Suppl 1 Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones	2002
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. Journal of Korean medical science, 2002, Volume: 17, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2002
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy, 2002, Volume: 48, Issue:6 Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors	2002
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene. International journal of antimicrobial agents, 2003, Volume: 22, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines	2003
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Nov-01, Volume: 37, Issue:9 Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2003
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagnostic microbiology and infectious disease, 2003, Volume: 47, Issue:4 Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae	2003
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-15, Volume: 38 Suppl 4 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies	2004
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. International journal of antimicrobial agents, 2005, Volume: 25, Issue:2 Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome	2005
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines	2005
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2005, Volume: 11, Issue:9 Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae	2005
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2006
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:4 Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2006
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:4 Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Streptococcus pneumoniae; Topoisomerase II Inhibitors	2006
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae	2007
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clinical therapeutics, 2007, Volume: 29, Issue:12 Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gemifloxacin; Humans; Monte Carlo Method; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Respiratory Mucosa	2007
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population. The International journal of artificial organs, 2008, Volume: 31, Issue:9 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Prosthesis-Related Infections; Quinolines; Quinolones; Staphylococcal Infections; Staphylococcus epidermidis	2008
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010, Volume: 29, Issue:11 Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline	2010
Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. International journal of antimicrobial agents, 2011, Volume: 38, Issue:3 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Humans; Listeria monocytogenes; Macrophages; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Staphylococcus aureus	2011
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin	2012
Simultaneous determination of fluoroquinolones in environmental water by liquid chromatography-tandem mass spectrometry with direct injection: A green approach. Journal of chromatography. A, 2015, Oct-30, Volume: 1418 Topics: Anti-Bacterial Agents; Brazil; Chromatography, Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Fresh Water; Gemifloxacin; Green Chemistry Technology; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical	2015
Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus. International journal of antimicrobial agents, 2016, Volume: 48, Issue:4 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Colony Count, Microbial; Fluoroquinolones; Gemifloxacin; Keratitis; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Naphthyridines; Rabbits; Staphylococcal Infections; Treatment Outcome	2016
Ecological risk assessment of pharmaceuticals in the receiving environment of pharmaceutical wastewater in Pakistan. Ecotoxicology and environmental safety, 2017, Volume: 136 Topics: Animals; Diclofenac; Ecology; Environmental Monitoring; Fishes; Fluoroquinolones; Gemifloxacin; Ibuprofen; Moxifloxacin; Naphthyridines; Pakistan; Risk Assessment; Sewage; Wastewater; Water Pollutants, Chemical	2017
New insights into resistance of Helicobacter pylori against third- and fourth-generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter, 2019, Volume: 24, Issue:5 Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Resistance, Bacterial; Gemifloxacin; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Molecular Docking Simulation; Moxifloxacin; Mutant Proteins; Mutation; Polymerase Chain Reaction; Protein Binding; Sequence Analysis, DNA	2019
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study. BMJ (Clinical research ed.), 2022, 10-04, Volume: 379 Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections	2022